Ficlatuzumab is a monoclonal antibody (McAb) targetinghuman hepatocyte growth factor(HGF). Ficlatuzumab blocks the activation of theHGF/c-Metsignaling pathway, and inhibitsc-Metreceptor-mediatedcancercell proliferation, migration, and invasion^[1].

HGF/c-Met^[1]

Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion^[1].
Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesenchymal transition (EMT), Vimentin expression in HNSCC cells^[1].
Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells^[1].
Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone^[1].

Liquid

1174900-84-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.